Latest / Age Defiantly with Mark Young / [Ep 34] ED Isn’t Just “Performance”—It’s a Heart Health Warning | Dr. Nathan Bryan

Transcript

[Ep 34] ED Isn’t Just “Performance”—It’s a Heart Health Warning | Dr. Nathan Bryan · Age Defiantly with Mark Young

• 0:00
  Welcome to Performance Driven Living, the podcast where we question everything.
• 0:05
  We don't tip to around tough topics, we walk right into them, not to provoke, but to
• 0:11
  get closer to what's real.
• 0:13
  You might not agree with everything you hear, and that's okay.
• 0:17
  The show isn't about being right, it's about being real.
• 0:20
  These conversations are meant to stretch your thinking, challenge assumptions, and spark
• 0:25
  something deeper.
• 0:26
  The views shared are those of our guests and may not reflect those of the host or team.
• 0:32
  And while we dive deep into health, performance, and transformation, this is not medical advice.
• 0:38
  Talk to your doctor before making changes to your health or lifestyle.
• 0:42
  Take what lands, leave what doesn't, but whatever you do, don't stop questioning.
• 0:49
  We're here at the Performance Driven Living podcast at the Changing Life and Destiny Conference
• 1:00
  here in Plano, Texas.
• 1:02
  And I have the honor of talking to my friend, Dr. Nathan Bryan, who is just the king of
• 1:08
  nitric oxide.
• 1:09
  I mean, it's a better way to say that.
• 1:11
  I know you're products, the things that you've worked on.
• 1:14
  I've been familiar with Numa for years.
• 1:17
  Nathan, so the point of this podcast and what we do is, again, Performance Driven Living,
• 1:22
  right?
• 1:23
  It's my contention that people want to always live in a way, or the people I want to
• 1:28
  be around, anyways, want to live in a way that they can outperform you yesterday.
• 1:32
  It's that 1% better kind of mindset.
• 1:35
  How could we be better?
• 1:36
  I heard you in a talk the other day using that exact same metaphor and everything we talk
• 1:40
  about here is, how do we do better?
• 1:43
  How do we show up better in the world tomorrow than we did yesterday?
• 1:47
  And I happen to know that you're an expert on nitric oxide, which is this Nobel Prize-winning
• 1:52
  molecule that the world in many cases knows nothing about.
• 1:56
  That's right.
• 1:57
  And yet, it is a miraculous, I'm correct, but it's a miraculous molecule and the truth
• 2:03
  of the matter is, I mean, nitric oxide is everything from anti-aging to sports performance
• 2:09
  to fixing a reptile dysfunction, like-
• 2:12
  That's in as many ways as you can imagine, nitric oxide is a part of that.
• 2:16
  And I would just love it if it teach me, teach me whatever you have, and I want the audience
• 2:21
  to listen to what you have to say about how does nitric oxide just change the game?
• 2:26
  Well, you know, I've spent 25 years in the basic sciences and academia as a professor
• 2:31
  of medicine, really studying nitric oxide, how the human body makes it, what goes wrong
• 2:36
  in people that have lost the ability to make it?
• 2:39
  And then how do we fix that?
• 2:40
  How do we correct that?
• 2:41
  Because you touched on a lot of the high points.
• 2:45
  It's a vasodilator, so it's a gas that's produced in the lining of the blood vessel.
• 2:49
  And it dilates the blood vessels.
• 2:51
  And it basically eliminates the inflammation that we see in the lining of the blood vessel.
• 2:57
  So vascular inflammation, micro-inflammation, micro-vascular inflammation, that's really
• 3:02
  the earliest stages of cardiovascular disease or avalous sclerosis.
• 3:06
  But you know, it does so much more, it mobilizes our own stem cells, and helps repair and
• 3:10
  replace dysfunctional cells.
• 3:12
  It prevents our telomeres from getting shorter, so it extends our lifespan.
• 3:17
  And perhaps from an performance perspective, it improves mitochondrial function.
• 3:22
  So it's improving the efficiency of energy production with less oxygen.
• 3:28
  And it's improving mitochondrial biogenesis.
• 3:30
  So when we make adequate nitric oxide, we have normal blood flow.
• 3:33
  We can dilate blood vessels upon demand.
• 3:36
  We have less inflammation.
• 3:37
  In fact, some of my patents are the method of reducing inflammation with nitric oxide.
• 3:42
  Lower oxidative stress, immune dysfunction, everything we see with chronic disease, nitric
• 3:47
  oxide appears to addressing.
• 3:49
  I actually want to unpack that last statement, because you talked about oxidative stress.
• 3:54
  And I don't think most people understand exactly what oxidative stress is.
• 3:57
  It's a word that gets thrown around, particularly in our circles.
• 4:00
  But it gets used, I think, outside of these circles a little bit more than it used to
• 4:04
  now.
• 4:05
  And I tell people, like oxidative stress is literally the dichotomy of longevity.
• 4:13
  It's almost a matter of your body deals with oxidative stress through environmental toxins,
• 4:17
  through everything you can imagine.
• 4:19
  And the more oxidative stress builds up, eventually your body just can't handle the oxidative
• 4:23
  load.
• 4:25
  And then the oxidative stress begins the aging process.
• 4:27
  And it's like there's a tipping point for most people, because when you're young, your
• 4:30
  body is able to deal with it.
• 4:32
  And eventually the oxidative stress ends up building up through a point that your body
• 4:35
  just can't deal with it any longer, right?
• 4:37
  Yeah, it's rust.
• 4:38
  It's, I mean, that's what rust is in the environment.
• 4:41
  It's an oxidation of the iron.
• 4:43
  Yes.
• 4:44
  And oxidation is a loss of an electron.
• 4:46
  So when we become oxidized, we're losing electrons.
• 4:49
  Antioxidants are electron donors.
• 4:51
  Correct.
• 4:52
  So we get oxidative stress when we have an imbalance of antioxidants with prooxyns.
• 4:57
  And so what we've looked at biochemically is what are the primary sources of oxidative
• 5:01
  stress in the cell?
• 5:03
  In its NADPH oxidase, it's an uncouple electron transport chain.
• 5:07
  And it's actually the enzyme that makes nitric oxide becomes uncouple and it produces super
• 5:11
  oxide.
• 5:12
  Yes.
• 5:13
  So when we looked at the three primary sources of oxidative stress in the cell, then how
• 5:15
  do we fix that?
• 5:17
  And fortunately, nitric oxide fixes all those.
• 5:21
  So if you lose the ability to produce nitric oxide, you get over a production of super
• 5:24
  oxide from the NADPH oxidase.
• 5:26
  You're an electron transport chain of the mitochondria, become uncouple.
• 5:29
  Now, you're reducing molecular oxygen to super oxide.
• 5:32
  And we produce super oxide from the enzyme that's supposed to make nitric oxide.
• 5:36
  So we're talking about the danger of super oxide, though.
• 5:39
  Yes.
• 5:40
  So super oxide is an oxygen radical.
• 5:42
  And so oxygen radicals steal electrons.
• 5:45
  So they oxidize other molecules.
• 5:48
  Which net effect means that the problem makes the problem bigger.
• 5:51
  No, and it's a perpetual reaction because these oxygen radicals, which means that it
• 5:56
  has an unpaired electron and et cetera over it.
• 5:58
  So it's always trying to grab another electron to stabilize that configuration.
• 6:02
  So the only way to stop a radical reaction is with another radical.
• 6:06
  And nitric oxide is a radical.
• 6:07
  It's a free radical.
• 6:09
  But it's different than super oxide because it's a nitrogen, oxygen bond, and there's
• 6:14
  a polarity.
• 6:15
  So it's complex physical chemistry, yeah.
• 6:18
  So nitric oxide donate to the electron, which means it's antioxidant properties.
• 6:24
  So when nitric oxide donate to its electron to super oxide or hydroxyl radical, it
• 6:28
  neutralizes that free radical, that antioxidant, and it prevents oxidative stress.
• 6:33
  So it completely neutralizes the damage.
• 6:36
  So it's oxidative stress, of course, you know, for the audience to say, we're talking
• 6:39
  this is rust.
• 6:40
  That's right.
• 6:41
  You're resting from the inside.
• 6:42
  It gets rusty enough until it dies, you know, it's really, and I always go back to
• 6:46
  that tin man kind of analogy, right?
• 6:48
  Like tin man's out in the haunts of forest and, you know, I think things are just not
• 6:54
  working the way they did, but, you know, Dorothy comes along, gives them some oil, and
• 6:59
  things start working.
• 7:01
  He does his happy dance.
• 7:04
  Is there a way to reverse oxidative stress then?
• 7:07
  Absolutely.
• 7:08
  So again, it's a balance between antioxidants and pro-oxidants.
• 7:12
  So if we can stop the oxidative stress inside the cell, then that's a major step.
• 7:17
  The other thing is, you know, unfortunately we're exposed to a lot of toxins in the environment.
• 7:21
  The water we drink, the food we eat, things we're exposed to, the environment.
• 7:24
  Stress.
• 7:25
  Stress.
• 7:26
  So we have to eat an antioxidant rich diet, and then we need to do things that promote and
• 7:34
  limit the oxidative stress.
• 7:35
  And also get the oxidative stress out of our lives.
• 7:39
  Yeah, we have to understand that how do we, so there's, there's an electrical potential
• 7:44
  that's required to extract an electron from every molecule.
• 7:48
  And the redox potential is for glutathione is much different than a scorbic acid, and
• 7:52
  an alpha-lapoic acid, and all these known antioxidants.
• 7:56
  So we have to do is figure out what electrical potential do we need to prevent oxidation
• 8:01
  of certain biomolecules.
• 8:03
  And that's what really our research has been, one for the past 20 years.
• 8:06
  We know how to prevent oxidation of BH4 tetrahydribobterine that prevents nossum coupling, so
• 8:12
  we can maintain normal endothelial nitric oxide production and prevent that age-related loss.
• 8:17
  So I wanted to get into that endothelial production of nitric oxide for a small moment, because
• 8:22
  you know that cardiovascular health is a personal topic for me.
• 8:27
  When we talk about endothelial function, unpack that for me, because I want to draw some
• 8:32
  connections between that and blood pressure.
• 8:34
  Yeah.
• 8:35
  45.4% of the US population struggles with hypertension, or has it at least been diagnosed
• 8:40
  with hypertension, save all those that haven't been.
• 8:43
  How does this endothelial function connect there and nitric oxide's role on it?
• 8:48
  So the endothelial cells, or the single layer of cells that line all blood vessels start
• 8:52
  the bone.
• 8:53
  Right?
• 8:54
  It's your lymphatic cells, is lined by endothelial cells, and your entire cardiovascular
• 8:59
  system is lined by endothelial cells.
• 9:01
  So 40 years ago, it was thought the endothelium was a barrier, right?
• 9:04
  It was designed to keep things into the blood supply versus extravascular.
• 9:09
  And in 1980, it was recognized that the endothelium is a vasoactive, even an endocrine organ
• 9:15
  that secretes a molecule that causes the blood vessels to relax.
• 9:19
  And that was Bob Furchcott, who discovered this, what he called endothelium derived relaxing
• 9:23
  factor.
• 9:25
  And then in 1987, Luegnar discovered that EDRF is nitric oxide gets.
• 9:30
  So now the endothelium is a vasoactive organ system.
• 9:35
  And what we call endothelial dysfunction is when the enzyme enos, endothelial nitrogen
• 9:39
  oxide synthase, is no longer functional and can no longer produce nitric oxide, then
• 9:44
  we don't get vasodilation.
• 9:46
  In fact, we get vaso constriction.
• 9:47
  Correct.
• 9:48
  And then you get an upregulation of adhesion molecules, white blood cells, platelets,
• 9:53
  monocyte stature, Phil stick, and we get vascular inflammation.
• 9:56
  So I want to break that down for the audience a little bit in this idea that the endothelium
• 10:01
  is almost like I call it the thermostat of the cardiovascular system.
• 10:05
  It's the endothelial lining of the cardiovascular system that actually recognizes when the blood
• 10:12
  vessel needs to expand and contract.
• 10:14
  So it literally is the, it has to be responsive to agonist or stimulators or activators.
• 10:20
  If it's not, then we can't get the best example is during sexual function because erectile
• 10:26
  dysfunction is a symptom of nitric oxide deficiency.
• 10:30
  So if we're about to be intimate and we're stimulated, the body's response is to make
• 10:34
  nitric oxide in the sex organ, the blood vessels of the sex organs, we get dilation, we get
• 10:39
  engorgement, and that's an erection in men and women.
• 10:42
  But if you have endothelial dysfunction and the blood cells can make nitric oxide, you
• 10:45
  don't get vasodilation, you don't get engorgement in the calvator rectal dysfunction.
• 10:49
  That's correct.
• 10:50
  But if that endothelial dysfunction is occurring in the blood vessels of the sex organs, it's
• 10:55
  systemic.
• 10:56
  You've got the same dysfunction in the coronary arteries and the cerebral arteries.
• 10:58
  So it's really the canary in the coal mine that tells us, tells patients, tells people
• 11:05
  that you have endothelial dysfunction and you're on a slippery slope to a long set of
• 11:09
  cardiovascular disease.
• 11:10
  So we're running off topic here, but I like it.
• 11:13
  So tell me.
• 11:14
  So for instance, getting into this topic of a rectile dysfunction, then you've mentioned
• 11:18
  the canary in the coal mine.
• 11:20
  I'm curious from your position as a researcher in an nitric oxide specialist, let's say a man
• 11:25
  ends up being diagnosed with a rectile dysfunction or not diagnosed.
• 11:28
  I mean, he knows it.
• 11:29
  Yeah.
• 11:30
  So he knows.
• 11:31
  But we treat that like it's a sexual dysfunction issue when in fact, if somebody is diagnosed
• 11:38
  with a rectile dysfunction or a doctor like we're like, here's Viagra, here's Cialis,
• 11:42
  here's whatever here.
• 11:43
  This will fix this.
• 11:44
  But again, it's the medical community, then not to dog on the medical community, but
• 11:49
  maybe a little bit.
• 11:51
  We're passing out symptom reduction.
• 11:53
  And in fact, that is a symptom that tells you you've got a bigger cardiovascular problem
• 11:59
  and we're not dealing with that.
• 12:01
  Yeah.
• 12:02
  Thank you.
• 12:03
  We agree on that.
• 12:04
  I assume.
• 12:05
  No, without a doubt.
• 12:06
  So the challenge is, well, it's not a challenge, it's just the fact.
• 12:11
  So the PD5 inhibitors like the Viagras and the Cialis and LaVitra, they were approved
• 12:15
  in 1998.
• 12:16
  So 20, 27 years ago, right?
• 12:19
  And so we know from the clinical data that only 50% of the men that are prescribed
• 12:23
  Viagra, or Cialis for a rectile dysfunction, respond with better erections.
• 12:29
  So these drugs don't work in 50% of the people in which they're prescribed.
• 12:33
  Because when you understand how these drugs are working, they're called phosphidesterase
• 12:36
  inhibitors.
• 12:38
  So the way the relaxation occurs is, in the end of the female cells, when they're activated,
• 12:42
  they produce nitric oxide, nitric oxide's a gas, it diffuses into the smooth muscle that
• 12:47
  surrounds blood vessels.
• 12:48
  And then that nitric oxide binds to an enzyme called guanolocyclase, complex biochemistry,
• 12:53
  make a long story short.
• 12:54
  It leaves some increase in the second messenger, cubsiclic GMP, and it's cyclic GMP that allows
• 13:00
  for the calcium mobilization, smooth muscle relaxation.
• 13:03
  So phosphidesterase enzymes degrade cyclic GMP.
• 13:08
  Cyclic GMP is dependent upon nitric oxide production.
• 13:12
  So nitric oxide is upstream of PD5 activity.
• 13:17
  So the reason 50% of the people don't respond is because they're not making any nitric
• 13:21
  oxide in the philium of the blood vessels.
• 13:24
  So there's no increase in cyclic GMP, so there's no substrate for PD5 inhibitors to work
• 13:28
  on.
• 13:29
  The interruptions, it's up here.
• 13:30
  It's not down here.
• 13:31
  Yeah, it's like, it's like, what I say, it's like, it's dominoes, right?
• 13:36
  Nitric oxide is the first domino.
• 13:38
  Once that flips, it's a cascade.
• 13:41
  But if you don't flip that first domino, nothing else is going to happen.
• 13:45
  We're prescribing with the intention of fixing the third domino or the fourth domino.
• 13:50
  We're not fixing the first one, which doesn't even require a prescription.
• 13:53
  Now, that's right.
• 13:54
  It's diet, lifestyle, medical technology, it's pretty simple.
• 13:58
  Correct.
• 13:59
  Which is phenomenal, because obviously, a man who gets, you know, an erectile dysfunction
• 14:03
  problem is that it's an ego issue on top of everything else.
• 14:07
  Well, at least it's like a logical issue.
• 14:08
  It's a physiological issue, but then it leads to psychological issue.
• 14:11
  It leads to relational issues, leads to divorce, leads to all sorts of issues.
• 14:15
  And, and again, something I hate to say is basic as, but nitric oxide shouldn't be that
• 14:21
  big of a mystery to people, but it seems to be because word hasn't gotten out to explain
• 14:25
  to people the upstream, the preventative, but the extra in benefits of just having nitric
• 14:31
  oxide in the body.
• 14:32
  Yeah.
• 14:33
  So when you look at it from a mechanism of action and ideology standpoint, it's a symptom
• 14:36
  of nitric oxide deficiency, just like Alzheimer's and dementia is a symptom of chronic nitric
• 14:42
  oxide deficiency.
• 14:44
  Hypertension is a symptom of nitric oxide deficiency.
• 14:47
  Yes.
• 14:48
  So we got week today.
• 14:49
  We can address the root cause of all these chronic diseases and not just treat the symptoms
• 14:53
  because similar to erectile dysfunction and you brought it up, 50% of the people that
• 14:57
  are given anti-hypertensive medications for their high blood pressure don't respond with
• 15:01
  better blood pressure.
• 15:02
  Correct.
• 15:03
  And why is that?
• 15:04
  Because they're put on an ACE inhibitor, an ARB, your calcium channel blocks isn't the
• 15:07
  problem.
• 15:08
  No, the problem isn't a rate of an angiotensin or kidney issue.
• 15:11
  Nitric oxide addresses the physics of blood pressure.
• 15:15
  So we have a finite amount of blood pumping through our body at any given time.
• 15:19
  If we make nitric oxide, we dilate the blood vessels, now we've got the same volume going
• 15:22
  through bigger pipes.
• 15:23
  If we can't make nitric oxide, we're chronically constricted.
• 15:27
  If the same volume of blood going through smaller pipes, physics tells us pressure goes
• 15:31
  up.
• 15:32
  If we give nitric oxide or restore nitric oxide, we'd vasodilate, blood pressure comes
• 15:36
  down and it's normal.
• 15:38
  And all we're doing is put an additional strain on the heart over and over again because
• 15:41
  you're making it force fluid through a smaller opening.
• 15:45
  Yeah.
• 15:46
  And then you get left intriguing to hypertrophy, you get a hard failure and people die.
• 15:50
  Yeah.
• 15:51
  And again, it's a very simple thing.
• 15:52
  This is going to talk together day here at the conference and is we're talking 50% of
• 15:56
  the US population have been diagnosed with hypertension.
• 16:00
  What exactly is the definition of a pandemic?
• 16:05
  We're blowing whistles on pandemic level stuff all over the place, but why is this not?
• 16:10
  Why is this not a conversation that we're having about hypertension and how this is
• 16:14
  affecting things?
• 16:15
  And that again, especially considering the solution is only 50% effective.
• 16:19
  Yeah.
• 16:20
  And the fact that cardiovascular disease remains a number one killer today worldwide is
• 16:24
  simply inaccessible, unacceptable because we know we know what causes it.
• 16:29
  We know how to diagnose it and there's technology to treat it.
• 16:32
  So for me, it's just it's a lack of translation of the science and it's a lack of being able
• 16:37
  to penetrate into the pharma model of continuously mitigating.
• 16:42
  I'm going to put you in the spot.
• 16:43
  Why do you think that?
• 16:44
  Yeah.
• 16:45
  But in a sense of business, it's a for profit business.
• 16:47
  In fact, it's the most profitable business enterprise in the world, especially in the US,
• 16:54
  especially in the US.
• 16:55
  We have 4% of the population and we prescribe 60% of the global drugs, which is and we have
• 17:00
  the sickest population on earth.
• 17:01
  So just the bad date itself tells us that drug therapy is now making anyone better.
• 17:07
  You'd think, right?
• 17:08
  And you'd think more people would be jumping on board at this.
• 17:10
  Now Nathan, I know you've been working on a lot of other projects and you've got your
• 17:14
  fingers and a new upcoming clinical trial talking about nitric oxide and its effectiveness
• 17:20
  and wanting to prove that from an FDA perspective as well as getting more products on the market
• 17:26
  to do this.
• 17:27
  What do you got?
• 17:28
  Tell me what you're working on.
• 17:29
  Well, you know, we try to number one, understand what goes wrong and people that can't make
• 17:33
  nitric oxide and then provide solutions to that.
• 17:36
  So we've had dietary supplements on the market for a number of years.
• 17:41
  We've got topical products for skin care and beauty.
• 17:44
  We just launched an oral line of products, toothpaste, mouth rinse, that's targeting the
• 17:49
  oral microbiome.
• 17:50
  As opposed to mouth wash, which is killing us away from our mouth.
• 17:52
  We want to support the microbiome.
• 17:54
  We don't want to kill and destroy.
• 17:56
  But we're also, you know, I was trained as a drug discovery bio-kills.
• 18:00
  So I'd never intended to develop dietary supplements or could see products.
• 18:04
  Right.
• 18:05
  The opposite.
• 18:06
  The opposite.
• 18:07
  Right.
• 18:08
  Understand the mechanism of disease to the extent that we can develop rational therapies.
• 18:12
  So we're working on an nitric oxide releasing, uh, uh, uh, lozons for a schemic heart disease.
• 18:18
  Uh, you know, 33 million Americans live with a schemic heart disease, 250 million people
• 18:22
  worldwide.
• 18:24
  The cornerstone therapy is Isis Orbide or nitriblister.
• 18:27
  Uh, it, it's effective at the acute symptomatic relief of angina, but it's the data tell us
• 18:32
  that the longer patients are on the organic nitrates, the worse they get.
• 18:35
  So there's a huge demand for that.
• 18:38
  And our pre, our clinical data shows that the laws and will dilate the coronary arteries
• 18:42
  relief, angina, prolonged exercise, induced angina with no tolerance.
• 18:47
  So we're trying to get that through the FDA, which will start a clinical trial later this
• 18:50
  year.
• 18:51
  We've got a drug for Alzheimer's and we're making a topical drug for diabetic ulcers
• 18:54
  and non-healing wounds.
• 18:56
  You see, you mentioned organic nitrates, which makes me want to go back because I immediately
• 19:00
  go to beats.
• 19:01
  Immediately goes.
• 19:02
  Well, that's what's called an organic nitrate.
• 19:04
  So it is.
• 19:05
  Organic nitrates are nitriblister and Isis Orbide die nitrate, Isis Orbide mononitrate.
• 19:10
  So these are, these are chemical compounds that have a glycerol backbone of different
• 19:16
  nitro groups on that have to be metabolized in the nitric oxide by the mitochondria.
• 19:20
  So the pay, they don't, they're not spontaneous nitric oxide donors, they have to be metabolized
• 19:25
  and it overwhelms the cell and the system and you become tolerant to it.
• 19:29
  Got it.
• 19:30
  And that's creating a decline in performance.
• 19:32
  And yeah, it makes in the female function worse, creates oxidative stress, and so long
• 19:37
  term use of these drugs is not a good idea.
• 19:39
  So there's, there's a severe unmet need, just like in most poorly managed chronic diseases
• 19:45
  in the US or worldwide.
• 19:48
  So for people who are looking to get more information about you, more information about
• 19:52
  nitric oxide, Numa, any number of the companies that you're involved in right now, where
• 19:56
  would they do that?
• 19:57
  You know, I send people to my YouTube channel because we provide all Sonsan education
• 20:02
  awareness.
• 20:03
  It's Dr. Nathan S. Brian, nitric oxide, Dr. Nathan S. Brian, and that's B.R.
• 20:08
  Y.
• 20:09
  The R.Y.
• 20:10
  Nitric oxide.
• 20:11
  I just published a new book, J. Bolston, Brick Tower Press is my publisher, Alan Morelle
• 20:17
  and Creative Management Partner, my agent called the secret of nitric oxide bringing the
• 20:21
  science to life where I tell really the story of nitric oxide, what it is, what it does,
• 20:27
  what led to a Nobel Prize.
• 20:29
  And in that book, I intertwined my kind of a personal life, my series of discoveries
• 20:36
  that we made in academia and patents, the development of product technology, what nitric
• 20:41
  oxide does in Alzheimer's, diabetes, sports performance, really taking the complex science
• 20:48
  and hopefully putting it into an easy to comprehend play rate, but, you know, that's a great
• 20:52
  resource.
• 20:53
  I'm searchable on most search engines.
• 20:56
  What an audio too.
• 20:57
  It is on audio.
• 20:58
  We're having it translated now to Portuguese, German, Chinese, Spanish, perhaps Italian.
• 21:07
  I'm going to probably listen in English.
• 21:12
  That's going to actually have the best comprehension for me.
• 21:14
  And then to follow our drug discovery, it's brinetherapyutics.com, our drug programs
• 21:18
  for our consumer products, where n101.com, that's one nitrogen, the letter n, number one,
• 21:25
  letter o, number one.com, n101.com, n101.com, and then brinetherapyutics.com, and let's
• 21:32
  be our YA and again, brinetherapyutics.
• 21:34
  And I look forward to having future conversations with you, buddy.
• 21:38
  So we have a lot to talk about.
• 21:40
  All right.
• 21:41
  Appreciate it.
• 21:42
  Yeah.